Home » Stocks » NKTX

Nkarta, Inc. (NKTX)

Stock Price: $48.42 USD -0.38 (-0.78%)
Updated Feb 26, 2021 10:28 AM EST - Market open
Market Cap 1.59B
Revenue (ttm) 385
Net Income (ttm) n/a
Shares Out 30.98M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $48.42
Previous Close $48.80
Change ($) -0.38
Change (%) -0.78%
Day's Open 47.88
Day's Range 46.35 - 50.77
Day's Volume 57,412
52-Week Range 22.46 - 79.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies ...

GuruFocus - 1 week ago

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LEGN, LLY, RHHBY, RNA
GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies ...

GlobeNewsWire - 3 months ago

First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies ...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies ...

GlobeNewsWire - 4 months ago

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager , J.D., Ph.D. to Join as Chief Legal Officer

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapi...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapi...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapie...

Benzinga - 7 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, PSTX, AKRO, AZZ, GSK, PRSP, TSE, WCC
Benzinga - 7 months ago

Nkarta Inc. (NASDAQ: NKTX) announced on Tuesday the underwriters for its initial public offering have completely exercised their overallotment option to purchase 2.1 million additional shares.

Market Watch - 7 months ago

Nkarta Inc. NKTX, -6.41% said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments.

GlobeNewsWire - 7 months ago

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million

InvestorPlace - 7 months ago

The Nkarta (NKTX) IPO is underway for the cancer research company and it has it offering 14 million shares on the Nasdaq. The post Nkarta IPO: 13 Things for Potential NKTX Stock Investors to K...

Market Watch - 7 months ago

Shares of Nkarta Inc. tripled out of the gate Friday, after the biotechnology company's initial public offering priced above its expected range.

Market Watch - 7 months ago

Nkarta Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million.

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre...

About NKTX

Nkarta, a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
CEO
Paul J. Hastings
Stock Exchange
NASDAQ
Ticker Symbol
NKTX
Full Company Profile

Financial Performance

In 2019, Nkarta's revenue was $115,385, a decrease of -98.24% compared to the previous year's $6.55 million. Losses were -$21.08 million, 7,577.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Nkarta stock is "Strong Buy." The 12-month stock price forecast is 82.00, which is an increase of 69.35% from the latest price.

Price Target
$82.00
(69.35% upside)
Analyst Consensus: Strong Buy